Intranasal Cooling for Encephalopathy Prevention Phase 1
Teaming Collaborator: Temple University, Pa.
The design of the ruggedized hypothermia therapy (THT) delivery device to mitigate the effects of brain trauma was guided in part by indirect evidence from theoretical and computational modeling calculations and by direct evidence obtained from empirical bench top and in vivo testing. Our Phase 1 goal was to improve the efficiency of perfluorochemical (PFC) vaporization in order to reduce the fluid load and flow requirements associated with the latent heat of cooling process so as to reduce the equipment burden for field, point of care as well as transport applicability of aerosolized PFC nasopharyngeal preferential brain cooling approach. Further to understand how our design would impact patient outcomes.
The Phase 1 effort will guide the system development in Phase 2, which is currently pending, as follows: 1) design and develop a functional THT system based on Phase 1 outputs, 2) in vitro model testing applying fundamental thermodynamic principles, utilizing heat transfer instrumentation and principles of calorimetry to evaluate the temperature output, PFC particle size and mass emitted from a patient interface as a function of specific PFC species, gas and PFC flows and flow ratios; 3) perform testing using the newly designed device to deliver a down select of PFC species, gas and PFC flows and ratio to test the profile and evaluate efficiency; and 4) progressively verify and validate this device with in vivo testing on brain injured animals in a controlled environment to gain insight regarding efficacy as a function of scale and underlying physiology.